A randomized phase II study of S-1 monotherapy versus cisplatin with vinorelbine for completely resected stage II/IIIA non-small cell lung cancer: rationale and study protocol design for the LOGIK1702 study by Tsuchiya Tomoshi et al.
STUDY PROTOCOL Open Access
A randomized phase II study of S-1
monotherapy versus cisplatin with
vinorelbine for completely resected stage
II/IIIA non-small cell lung cancer: rationale
and study protocol design for the
LOGIK1702 study
Tomoshi Tsuchiya1* , Keitaro Matsumoto1, Takuro Miyazaki1, Ryoichiro Doi1, Shoji Tokunaga2,
Hiroyuki Yamaguchi3, Koichi Tomoshige1, Hironosuke Watanabe1, Takeshi Nagayasu1 and Kenji Sugio4
Abstract
Background: The current standard postoperative treatment for stage II-IIIA non-small cell lung cancer (NSCLC) is a
regimen of platinum doublet adjuvant chemotherapy. These regimens, which are the same as for solid NSCLC
tumors, often cause severe adverse reactions in the treated patients. Therefore, an effective treatment regimen with
fewer side effects is needed.
Methods/design: The purpose of this study is to evaluate the effectiveness and safety of S-1 monotherapy (80 mg/
m2 orally administrated twice daily, at day 1–14, 16 cycles) and cisplatin with vinorelbine combination therapy
(cisplatin 80 mg/m2 at day 1,vinorelbine 25 mg/m2 at day 1, 8, 4 cycles) in patients with II/IIIA stage non-small-cell
lung cancer who underwent a total resection. In addition, we will also evaluate the level of treatment side effects
by assessing quality of life (QOL), work productivity and activity performance. The primary endpoint is a 2-year
relapse free survival (RFS) and the second primary endpoints are 2-year overall survival (OS), rate of treatment
completion, safety, work productivity and activity, and quality of adjusted life years (QALY). At the same time, we
aim to obtain precise information required to perform future phase 3 randomized controlled trials. The study is
designed to estimate the primary endpoint with accuracy determined as the width of its 95% confidence interval
to be less than 20%. Recruitment started in May 2017 and is ongoing.
Discussion: This study has been conceived to establish a superior regimen for completely resected NSCLC based
on efficacy, safety and QOL.
Trial registration: Registry number: UMIN000027435. Registered May 22, 2017.
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Background
Lung cancer remains the leading cause of cancer-related
deaths worldwide. In order to prevent lung cancer recur-
rence, adjuvant chemotherapy in post-operative patients
with stage IB-IIIA non-small cell lung cancer (NSCLC)
has been established as the standard treatment [1–3].
The standard regimen for adjuvant chemotherapy is
intravenous administration of a platinum doublet [3].
However, the representative regimen of cisplatin
(CDDP) with vinorelbine (VNR) causes grade three or
four adverse reactions including severe leukopenia, neu-
tropenia, anemia, aspartate aminotransferase (AST) ele-
vation, nausea, vomiting, constipation, asthenia, injection
site reaction, and prolonged peripheral neuropathy in
more than 70% of patients. Renal dysfunction often oc-
curs and sometimes remains lifelong. Given the severe
adverse reactions to this standard adjuvant chemother-
apy and the fact that there are few remnant malignant
cells in the postoperative patients, milder treatment op-
tions have been considered.
A recent study of the 5-year survival in a randomized
phase III study of cisplatin with pemetrexed versus cis-
platin with vinorelbine for completely resected stage II-
IIIA non-squamous NSCLC (the JIPANG study) was re-
ported (ASCO 2019 8501). The JIPANG study failed to
show the superiority of pemetrexed plus cisplatin over
vinorelbine plus cisplatin and the cost of pemetrexed is
high. However, the regimen will be considered as an op-
tion for adjuvant chemotherapy for stage II-IIIA non-
squamous NSCLC since the effect is comparable and the
patients treated with cisplatin and pemetrexed had a
higher completion rate with low adverse reactions com-
pared to the patients treated with cisplatin and vinorel-
bine. Another recent approach is the use of immune
checkpoint inhibitors (ICI) for postoperative patients.
Several clinical trials of ICI with/without chemotherapy
are currently underway in adjuvant setting [4]. The trials
are expected to be completed during 2024 or later. Thus
the efficacy and the adverse reactions of ICI in adjuvant
therapy remain unclear.
S-1 might be another candidate for mild adjuvant
chemotherapy for NSCLC. The oral fluoropyrimidine
derivative which consists of tegafur and two modulators,
5-chloro-2,4-dihydroxypyridine (CDHP) and potassium
oxonate (Oxo), enhances 5-FU efficacy by inhibiting deg-
radation of 5-FU and reduces the GI toxicity caused by
5-FU [5]. The significant effects with low adverse reac-
tions of S-1 monotherapy in an adjuvant treatment have
been proven in randomized phase III trials in digestive
cancers including gastric, pancreatic and colon adeno-
carcinomas [6–8]. Accordingly, S-1 based adjuvant
chemotherapy has been used as an option of standard
treatment in intestinal cancers. Further, S-1 also has effi-
cacy against squamous cell carcinomas including head
and neck, oral, esophagus and thymus [9–11], suggesting
S-1 is effective on both squamous carcinomas and
adenocarcinomas.
Feasibility studies of S-1 based adjuvant chemotherapy
for patients with stage IB to IIIA NSCLC have also been
conducted [12, 13] . The results indicate that the com-
pletion rates of planned one-year treatment courses were
comparable to platinum doublet (50–72%) and the grade
3 adverse reactions were very low (4–20%) with no grade
4 adverse reactions. The grade 3/4 neutropenia was ex-
tremely low (0–6.7%), compared to the meta-analysis of
cisplatin with vinorelbine adjuvant chemotherapy of 80%
[14]. The 5-year overall and relapse free survival rates of
the S-1 treated postoperative patients with stage IB-IIIA
NSCLC were 72.5 and 67.5%, which are obviously better
than those of previously reported studies including plat-
inum doublet based adjuvant chemotherapies [12]. The
randomized phase II study of adjuvant chemotherapy
with S-1 and cisplatin with S-1 revealed that the survival
rates of both groups overlap in patients with completely
resected stage II–IIIA NSCLC [15], indicating that S-1
monotherapy has the potential for replacing the standard
regimen of platinum doublet by virtue of its efficacy and
safety.
The low incidence of adverse reaction directly corre-
lates with the quality of life of the treated patients. Be-
cause of mild adverse reactions, S-1 can be
administrated for outpatients without hospitalization
and treated patients can continue daily life and working,
which will maintain the social productivity of the treated
individuals. The evaluation of quality of life (QOL) and
work productivity of postoperative patients shows the
advantage of S-1 chemotherapy versus standard plat-
inum doublet adjuvant chemotherapy. Taken together,
these findings have enabled us to design the current
phase II study to confirm the beneficial effects of S-1 in
adjuvant chemotherapy. In this article, we describe the
protocol (version 2; January 14, 2020) for this study. The
results of this study are expected to provide basic infor-
mation for raising the precision of performance for a
randomized phase III study.
Methods/design
Study design and treatment
The present study is a multicenter, phase II, randomized,
open-labelled, parallel-group comparison study of the ef-
ficacy and safety of S-1 compared with cisplatin plus
vinorelbine for adjuvant therapy in patients with NSCL
C. The study design is summarized in Fig. 1. Patients are
randomized in a 1:1 ratio to the experimental arm (1
year of S-1 administration) or control arm (four cycles
of cisplatin with vinorelbine administration), stratified
according to sex (female vs. male), age (< 70 years vs. 70
years), pathologic stage (II vs. IIIA) and pathology
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(squamous cell carcinoma vs. non- squamous cell car-
cinoma). The primary endpoint is 2-year relapse-free
survival (RFS). The secondary endpoints are 2-year over-
all survival (OS), rate of treatment completion, safety,
work productivity and activity, and quality of adjusted
life years (QALY). QALY is calculated by the time points
of QOL converted from the questionnaire method using
Euro QoL 5 dimensions (EQ-5D-5L) [16] and conver-
sion chart. The EQ-5D-5L and work productivity and
activity impairment (WPAI) are surveyed by question-
naires for one and a half years from the start of adjuvant
chemotherapy (Fig. 2).
The study is being conducted at 30 institutions in the
Lung Cancer Group in Kyusyu (LOGIK) in Japan. The
study is registered with the University Hospital Medical
Information Network Clinical Trials Registry (www.
umin.ac.jp/ctr/) under registration number UMIN00002
7435. We conduct the study in accordance with the
principles of the Declaration of Helsinki. The central
ethics committee approved the study.
All eligible patients will be selected and approached on
the basis of information derived from the electronic
health records of these 30 institutions (academic hospi-
tals) according to the inclusion and exclusion criteria.
Participants will be provided with an explanation about
the study by their treating physicians, and they will be
asked to voluntarily sign an informed consent before
participation. If the patient’s consent is obtained, a clin-
ical trial physician will perform the observation/examin-
ation based on the description in Fig. 2a and b.
Eligibility criteria
The main patient inclusion and exclusion criteria are de-
tailed in Table 1.
Treatment
Arm A (S-1 monotherapy) is an adjuvant therapy of S-1
for 16 courses (1 year). S-1 80 mg/m2 is orally adminis-
tered twice daily (after breakfast and dinner) from after
breakfast at day 1 to after dinner at day 14 (or from after
dinner at day1 to after breakfast at day 15) as 21 days of
1 course.
Arm B (Cisplatin with vinorelbine combination ther-
apy) is an adjuvant therapy of cisplatin with vinorelbine
for 4 courses. Cisplatin 80 mg/m2 at day1 and vinorel-
bine 25 mg/m2 at day 1, 8 are administered as 21 days of
1 course for 4 courses.
Randomization
After the acquisition of written informed consent and
the completion of baseline measurements, the enrolled
participants are registered and assigned treatment by the
registration center. Participants will be randomly allo-
cated at a ratio of 1:1 (S1 versus Cisplatin with vinorel-
bine). Randomization will be performed using the block
randomization method with randomly varying block
length utilizing SAS version 9.4 software (SAS Institute,
Cary, NC, USA).
Statistical design and sample size considerations
This aim of this study is to estimate the 2 year relapse-
free survival rate (RFS) for each study arm with suffi-
cient clinical precision. The statistical comparison of the
difference in RFS between the two arms is not a primary
aim. We designed the sample size to estimate the 2-
year-RFS with the accuracy determined to be the width
of the 95% confidence interval for the 2 year-RFS to be
less than 20%. The 2-year RFS was expected to be 65%.
Assuming an estimate at the 95% confidence interval for
the 2 year-RFS with the Wilson’s method, 84 patients are
necessary for each arm. Estimating around 10% drop
outs, we set the total number of patients to be 190. The
above sample size was set to assure the statistical power
to quantitatively compare the primary point between the
arms. The primary goal of this study is to evaluate the
clinical significance of the S1 monotherapy by integrat-
ing the observed data of the RFSs, QOL and adverse
events of the two arms.
Relapse-free survival was defined as the time from the
date of the start of treatment to the date of disease
Fig. 1 Study Design of LOGIK1702 Study, A Randomized Phase II Study of S-1 and Cisplatin with Vinorelbine for Completely Resected Stage
II/IIIA NSCLC
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A
B
Fig. 2 Treatment schedule and outcome measures of arm A (2A) and arm B (2B). ●; Measurements, ▲; Measurable facilities (Once a month), △;
optional. *1; Measurements at every 90 (±30) days until 3 years from the start of the treatment. Every 180 (±60) days thereafter.*2; Measurements
at every 180 (±60) days until 3 years from the start of the treatment. Every 365 (±90) days thereafter. *3: Measurements at 365 (±60) days and
545(±60) days. CT Computed tomography, MRI Magnetic resonance imaging, RI Radio isotope, PET Positron emission tomography, WPAI Work
productivity and activity impairment questionnaire
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progression or death (whichever occurs first) or the date
of last contact. Overall survival was defined as the time
from the date of the start of treatment to the date of
death or last contact. The Kaplan-Meier method will be
used to estimate the time-to-event functions of relapse-
free survival and overall survival. The log-rank test will
be conducted as a reference without setting the signifi-
cance level.
Discussion
Since 2004, cisplatin with vinorelbine has been the pre-
ferred treatment for patients who have undergone
complete resection of stage II to IIIA NSCLC and the
recommended regimen has not been changed in more
than 16 years. Because the adverse reactions are severe
in the cisplatin with vinorelbine regime, the Lung Can-
cer Group in Kyusyu (LOGIK) is conducting the
LOGIK1702 study in order to compare the efficacy of
milder chemotherapy using S-1 compared to the stand-
ard regimen of cisplatin with vinorelbine. S-1 chemo-
therapy has been successfully used for other cancers and
is recommended for intestinal adjuvant chemotherapy.
In previous studies using cisplatin doublet based adju-
vant chemotherapies most of the relapses occurred
within 2-years following the operation and the survival
curve came to a plateau thereafter [1–3, 15]. In order to
estimate the efficacy of the two regimens, the primary
endpoint of this study is also configured as 2-year RFS.
The other aspect of this study is to evaluate work prod-
uctivity and activity, and quality of adjusted life years
(QALY) by using the questionnaire of the EQ-5D-5L,
which was configured as a secondary endpoint. The EQ-
5D-5L measures five aspects of the patient’s life: mobil-
ity, self-care, usual activities, pain/discomfort and anx-
iety/depression. Accordingly, the patients’ QALY will be
expressed numerically and evaluated objectively. Since
better QOL and work productivity are also desired even
for postoperative patients, this analysis will evaluate an-
other aspect of the adjuvant chemotherapy in addition
to prognosis. Quality of life is important as well as the
longevity prognosis. To the best of our knowledge, this
is the first prospective study which evaluates the QALY
and work productivity in postoperative adjuvant
chemotherapy.
The limitation of the present study is that this ran-
domized study is not aimed at evaluating statistical
comparison of the difference in prognoses between
the two arms. Rather, this study is aimed at providing
basic information for improving the performance
evaluation of a future randomized phase III study.
The LOGIK1702 study will give us new information
on the optimal chemotherapy regimen for completely
resected NSCLC.
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Table 1 Main Inclusion and Exclusion Criteria
Inclusion Criteria
1) Patients providing the written informed consent
2) Patients with non-small-cell lung cancer histopathologically
confirmed
3) Patients with total resection in pathological clinical stage II - IIIA with
more than one lobe excision was carried out
4) Patients with lymphadenectomy more than ND2a-1 or selective
lymphadenectomy
The selection method of the mediastinal lymph node dissected obeys
the following criteria
●Right upper lobe lung cancer (LC); No.2R,4R
●Left upper lobe segmentum superius LC; No. 4 L-6
●Right middle lobe LC; No.2R,4R,7
●Left upper lobe lingual LC; No.4 L-7
●Right lower lobe LC; No.7–9
●Left lower lobe LC; No.7–9
5) Patients without pre-treatment (radiation, chemotherapy) other than
surgical treatment
6) Patients who passed more than 28 days and less than 56 days after
the operation at enrollment
7) Patient is at least 20 years and less than 75 years of age (at enrollment
date).
8) Patients capable of treatment with oral medicine.
9) Eastern Cooperative Oncology Group (ECOG) performance status of
0–1
10) Patients having sufficient bone marrow, liver and renal function
tolerable to chemotherapy
Exclusion Criteria
1) Patients with active double cancer (synchronous double cancer and
asynchronous double cancer within 5 years of progression-free
period)
2) Patients with anamnesis of drug-induced hypersensitivity.
3) Patients with severe postoperative complications (such as
postoperative infection, rapture suture).
4) Patients with severe complications (such as diarrhoea, intestinal
paralysis, ileus, uncontrollable diabetes mellitus, heart failure, kidney
failure, liver failure).
5) Patients with interstitial pattern recognized as apparent interstitial
pneumonia in chest CT.
6) Patients with active infection.
7) Female patients pregnant or possibly pregnant (will), or nursing.
8) Patients under treatment with a type of fluorinated pyrimidine
antineoplastic.
9) Patients under treatment of flucytosine.
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